Newsfeeds - Spark Newswire

1 minute read

JonesTrading Initiates Coverage On Satsuma Pharmaceuticals with Buy Rating, Announces Price Target of $14

Today, 9:38 AM

JonesTrading analyst Sean Kim initiates coverage on Satsuma Pharmaceuticals (NASDAQ:STSA) with a Buy rating and announces Price Target of $14.

STSA

2 minute read

Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 9:38 AM

Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and…

AVTX

5 minute read

This Healthcare Stock Jumps Around 188%, Here’s 83 Biggest Movers From Yesterday

By Lisa Levin

Today, 9:38 AM

Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.

AFIB

3 minute read

5 Biotech Stocks To Watch During The Week Of June 13

By Shanthi Rexaline

Today, 9:38 AM

Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a compilation of five stocks that should be on your radar in the week of June 13: 1. Novavax

ACAD

1 minute read

Mizuho Remains Bullish On This Small-Cap Stock’s Migraine Candidate, But Why Did It Cut Price Target

By Vandana Singh

Today, 9:38 AM

Mizuho Securities says that the Satsuma Pharmaceuticals Inc (NASDAQ: STSA) story is essentially unchanged. It remains bullish on STS101's potential as an effective, safe, and reliable intranasal dihydroergotamine (DHE) for migraine.

IMPL

1 minute read

Mizuho Maintains Buy on Satsuma Pharmaceuticals, Lowers Price Target to $13

By Benzinga Newsdesk

Today, 9:38 AM

Mizuho analyst Vamil Divan maintains Satsuma Pharmaceuticals (NASDAQ:STSA) with a Buy and lowers the price target from $15 to $13.

STSA

2 minute read

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight

By Shanthi Rexaline

Today, 9:38 AM

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that moved stocks during the week.

ACAD